Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo.
- Resource Type
- Article
- Authors
- Huang, Zeyu; Han, Yijia; Zhang, Xiaotuan; Sun, Yao; Lin, Yuzhan; Feng, Luozhu; Zhou, Tieli; Wang, Zhongyong
- Source
- BMC Microbiology. 11/3/2023, Vol. 23 Issue 1, p1-11. 11p.
- Subject
- *CEFTAZIDIME
*CARBAPENEMS
*ACETYLCYSTEINE
*DRUG resistance in bacteria
*MEMBRANE permeability (Biology)
*CELL permeability
*TREATMENT effectiveness
*BACTERIAL wilt diseases
- Language
- ISSN
- 1471-2180
Background: Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance. Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti-inflammatory effects. Results: This study found that NAC combined with CZA effectively inhibits the growth of CZA-resistant clinical Enterobacterales strains. The CZA/NAC combination inhibits biofilm formation in vitro and decreases bacterial burden in a mouse thigh infection model. The combination is biocompatible and primarily increases cell membrane permeability to cause bacterial death. Conclusions: These findings prove that the CZA/NAC combination has potential as a treatment for CZA-resistant Enterobacterales infections. [ABSTRACT FROM AUTHOR]